Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, comme… Read more
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) - Total Liabilities
Latest total liabilities as of September 2025: CN¥972.67 Million CNY
Based on the latest financial reports, Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has total liabilities worth CN¥972.67 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanxi C&Y Pharmaceutical Group Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Shanxi C&Y Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanxi C&Y Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanxi C&Y Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Virgin Australia Holdings Ltd
AU:VGN
|
Australia | AU$5.69 Billion |
|
PT Lippo Karawaci Tbk
PINK:PTLKF
|
USA | $23.31 Trillion |
|
Kido Group Corp
VN:KDC
|
Vietnam | ₫6.24 Trillion |
|
North American Construction Group Ltd
NYSE:NOA
|
USA | $1.01 Billion |
|
Sanyo Chemical Industries Ltd
F:XSI
|
Germany | €34.94 Billion |
|
Jasmine Telecom Systems Public Company Limited
BK:JTS
|
Thailand | ฿1.79 Billion |
|
Zhejiang Jianfeng Group Co Ltd
SHG:600668
|
China | CN¥2.00 Billion |
|
Central Reinsurance Corp
TW:2851
|
Taiwan | NT$38.63 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Shanxi C&Y Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanxi C&Y Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual total liabilities of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥949.55 Million | +45.05% |
| 2023-12-31 | CN¥654.64 Million | -23.40% |
| 2022-12-31 | CN¥854.64 Million | +9.26% |
| 2021-12-31 | CN¥782.23 Million | -15.70% |
| 2020-12-31 | CN¥927.91 Million | +6.73% |
| 2019-12-31 | CN¥869.43 Million | +54.03% |
| 2018-12-31 | CN¥564.47 Million | +3.11% |
| 2017-12-31 | CN¥547.42 Million | +14.59% |
| 2016-12-31 | CN¥477.74 Million | +9.59% |
| 2015-12-31 | CN¥435.93 Million | +21.71% |
| 2014-12-31 | CN¥358.17 Million | +10.82% |
| 2013-12-31 | CN¥323.21 Million | +83.65% |
| 2012-12-31 | CN¥175.99 Million | +44.98% |
| 2011-12-31 | CN¥121.39 Million | -7.51% |
| 2010-12-31 | CN¥131.25 Million | -7.51% |
| 2009-12-31 | CN¥141.91 Million | +20.82% |
| 2008-12-31 | CN¥117.45 Million | -- |